St. Jude Children's Research Hospital today announced the availability of one of the world's largest collections of leukemia samples from children and adults. The effort, called PROPEL (Public Resource of Patient-derived and Expanded Leukemias), aims to advance fundamental research on the biology of leukemia and to help develop cures by sharing unique patient-derived xenograft samples with researchers around the world.
All news from Hematology & Oncology
A cancer therapy based on fusing two types of cells into a single unit shows promise in strengthening existing treatments for acute myeloid leukemia. The approach joins blood platelets that carry cancer drugs with stem cells that guide the platelets into bone marrow where leukemia begins.
Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and at St. Jude Children's Research Hospital have discovered that this problem begins with remission-induction treatment and suggests that early intervention should be considered.
Currently, the only therapy for a metabolic liver disease is an organ transplant. Tracy Grikscheit, MD, an attending physician and regenerative medicine scientist at Children's Hospital Los Angeles, hopes to change that reality.
City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area.
Patients with blood cancers such as leukemia and lymphoma are often treated by irradiating their bone marrow to destroy the diseased cells. After the treatment, patients are vulnerable to infection and fatigue until new blood cells grow back
Children with pediatric acute lymphoblastic leukemia (ALL) gain weight during treatment, and researchers at St. Jude Children's Research Hospital have discovered that this problem starts during remission-induction treatment and suggests that early intervention should be considered.
In an article published online October 12, 2018, by Leukemia, Medical University of South Carolina investigators report that a new compound enhances the efficacy of proteasome inhibitors (PIs), the standard-of-care for the treatment of multiple myeloma (MM), in cell culture and in preclinical models.